Angela T. White

GSK R&D Stevenage
Stevenage, ENG, United Kingdom

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 21 publications

Mutagenic and carcinogenic potency determinations for NDMA support the cumulative dose assumption underpinning the less-than-lifetime Threshold of Toxicological Concern.

Mutagenic and carcinogenic potency determinations for NDMA support the cumulative dose assumption underpinning the less-than-lifetime Threshold of Toxicological Concern.

Journal: Archives of toxicology
Published: January 27, 2026

Impurity qualification requirements for drug-linkers related impurities used to generate antibody-drug conjugates.

Impurity qualification requirements for drug-linkers related impurities used to generate antibody-drug conjugates.

Journal: Regulatory toxicology and pharmacology : RTP
Published: July 18, 2025

Evaluating the lifetime cumulative dose as a basis for carcinogenic potency of nitrosamines - a key tenet underpinning less-than-lifetime approaches for establishing acceptable intake limits.

Evaluating the lifetime cumulative dose as a basis for carcinogenic potency of nitrosamines - a key tenet underpinning less-than-lifetime approaches for establishing acceptable intake limits.

Journal: Regulatory toxicology and pharmacology : RTP
Published: May 15, 2025

Resolution of historically discordant Ames test negative/rodent carcinogenicity positive N-nitrosamines using a sensitive, OECD-aligned design.

Resolution of historically discordant Ames test negative/rodent carcinogenicity positive N-nitrosamines using a sensitive, OECD-aligned design.

Journal: Mutagenesis
Published: August 15, 2024

Assessing the utility of common arguments used in expert review of in silico predictions as part of ICH M7 assessments.

Assessing the utility of common arguments used in expert review of in silico predictions as part of ICH M7 assessments.

Journal: Regulatory toxicology and pharmacology : RTP
Published: May 15, 2023

In Silico Approaches In Carcinogenicity Hazard Assessment: Current Status and Future Needs.

In Silico Approaches In Carcinogenicity Hazard Assessment: Current Status and Future Needs.

Journal: Computational toxicology (Amsterdam, Netherlands)
Published: April 04, 2022

Calculating qualified non-mutagenic impurity levels: Harmonization of approaches.

Calculating qualified non-mutagenic impurity levels: Harmonization of approaches.

Journal: Regulatory toxicology and pharmacology : RTP
Published: April 08, 2021

Use of less-than-lifetime (LTL) durational limits for nitrosamines: Case study of N-Nitrosodiethylamine (NDEA).

Use of less-than-lifetime (LTL) durational limits for nitrosamines: Case study of N-Nitrosodiethylamine (NDEA).

Journal: Regulatory toxicology and pharmacology : RTP
Published: December 17, 2020

Skin sensitization in silico protocol.

Skin sensitization in silico protocol.

Journal: Regulatory toxicology and pharmacology : RTP
Published: February 24, 2020

Genetic toxicology in silico protocol.

Genetic toxicology in silico protocol.

Journal: Regulatory toxicology and pharmacology : RTP
Published: February 26, 2019

Principles and procedures for handling out-of-domain and indeterminate results as part of ICH M7 recommended (Q)SAR analyses.

Principles and procedures for handling out-of-domain and indeterminate results as part of ICH M7 recommended (Q)SAR analyses.

Journal: Regulatory toxicology and pharmacology : RTP
Published: September 14, 2018

Managing emerging mutagenicity risks: Late stage mutagenic impurity control within the atovaquone second generation synthesis.

Managing emerging mutagenicity risks: Late stage mutagenic impurity control within the atovaquone second generation synthesis.

Journal: Regulatory toxicology and pharmacology : RTP
Published: June 15, 2018
Showing 1-12 of 21

Last Updated: 09/26/2026